journal article·2025-06Open access

Immunomodulating platelet-mimicking nanoparticles for AIE-based enhanced photodynamic immunotherapy against lung cancer

Yuan Zhang, Zhiji Wang, Jia Wang, Ya Lin, Huimin Gao, Pengpeng Wang, Shuangfei Zhu, Huae Xu, Xiaolin Li

Abstract

Lung cancer has become the leading cause of cancer related death worldwidely. Nowadays, immune checkpoint inhibitor (ICI) plays an important part in the treatment of lung cancer. However, immunologically cold tumor microenvironment (TME) hinders the therapeutic effect of ICIs. Herein, immunomodulating platelet-mimicking nanoparticles (DM@PM NPs) were designed by encapsulating the aggregation-induced emission (AIE) photosensitizer DTZ-TPA-DCN with acidic-sensitive bond modified DSPE-PEG-MET (MET, metformin) and then coating with a platelet membrane (PM). Notably, DM@PM NPs can selectively accumulate in tumor profiting from the tumor-targeting and antiphagocytic capabilities of PM. In the acidic tumor tissues, the acidic-sensitive released MET of DSPE-PEG-MET plays as a kind of ICI and degrades PD-L1 expression in TME. MET also facilitates AIE photosensitizer induced photodynamic therapy (PDT) via blocking mitochondrial oxidative phosphorylation, thus dramatically promotes immunogenic cell death (ICD) of tumor cells which could convert cold tumor to hot and facilitates MET realizing enhanced immunotherapy against cancer in turn. What's more, sub-lethal ROS induced by DM@PM NPs could also directly activate immune cells. Overall, we proposed an intelligent and cross-regulatory platelet-mimicking drug loading nano-carrier that could achieve photodynamic immunotherapy against in situ and distant tumors, which provides a potential for clinical therapy of lung cancer. • DM@PM NPs is an immunomodulating platelet-mimicking nanocarrier integrating aggregation-induced emission (AIE) photosensitizer and metformin in one platform. • DM@PM NPs achieves tumor targeting and acid-sensitively release at tumor site. • DM@PM NPs realizes photodynamic immunotherapy against in situ and distant tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
1. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Nanotechnology in the diagnosis and treatment of lung cancer10.1016/j.pharmthera.2019.02.010 ↗
3. The biology and management of non-small cell lung cancer10.1038/nature25183 ↗
4. First-line immunotherapy for non-small-cell lung cancer10.1200/JCO.21.01497 ↗
5. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial10.1001/jama.290.16.2149 ↗
6. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer10.1200/JCO.2003.10.038 ↗
7. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies10.1158/1078-0432.CCR-15-0560 ↗
8. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions10.1186/s12943-021-01489-2 ↗
9. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy10.1016/j.ejphar.2021.174404 ↗
10. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
11. Regulatory mechanisms of PD-1/PD-L1 in cancers10.1186/s12943-024-02023-w ↗
12. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L110.1016/j.molcel.2018.07.030 ↗
13. Metformin-based nanomedicines for reprogramming tumor immune microenvironment10.7150/thno.104872 ↗
14. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance10.1080/15384047.2024.2308097 ↗
15. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs10.1001/jamanetworkopen.2019.2535 ↗
16. Immune escape: a critical hallmark in solid tumors
17. Acquired resistance to immune checkpoint inhibitors10.1016/j.ccell.2020.03.017 ↗
18. Top 10 challenges in cancer immunotherapy10.1016/j.immuni.2019.12.011 ↗
19. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death10.1084/jem.20050915 ↗
20. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency10.1002/advs.202201734 ↗
21. Copper-based bio-coordination nanoparticle for enhanced pyroptosis-cuproptosis cancer immunotherapy through redox modulation and glycolysis inhibition
22. Nanoparticles destabilizing the cell membranes triggered by NIR light for cancer imaging and photo-immunotherapy10.1038/s41467-024-50020-w ↗
23. Applications and enhancement strategies of ROS-based non-invasive therapies in cancer treatment10.1016/j.redox.2025.103515 ↗
24. Integration of immunogenic activation and immunosuppressive reversion using mitochondrial-respiration-inhibited platelet-mimicking nanoparticles10.1016/j.biomaterials.2019.119699 ↗
25. Metformin mediated PD-L1 downregulation in combination with photodynamic-immunotherapy for treatment of breast cancer10.1002/adfm.202007149 ↗
26. Immune/hypoxic tumor microenvironment regulation-enhanced photodynamic treatment realized by pH-responsive phase transition-targeting nanobubbles10.1021/acsami.1c07323 ↗
27. Metformin liposome-mediated PD-L1 downregulation for amplifying the photodynamic immunotherapy efficacy10.1021/acsami.0c21743 ↗
28. Aggregation-induced emission photosensitizers: from molecular design to photodynamic therapy10.1021/acs.jmedchem.9b02014 ↗
29. Aggregation-induced emission of 1-methyl-1,2,3,4,5-pentaphenylsilole10.1039/b105159h ↗
30. Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance10.1038/s41467-017-02732-5 ↗
31. A biomimetic aggregation-induced emission photosensitizer with antigen-presenting and hitchhiking function for lipid droplet targeted photodynamic immunotherapy10.1002/adma.202102322 ↗
32. A near-infrared AIE probe for super-resolution imaging and nuclear lipid droplet dynamic study10.1039/D0QM00914H ↗
33. AIEgen-coupled upconversion nanoparticles eradicate solid tumors through dual-mode ROS activation10.1126/sciadv.abb2712 ↗
34. Metformin reduces endogenous reactive oxygen species and associated DNA damage10.1158/1940-6207.CAPR-11-0536 ↗
35. Platelet-cancer interactions10.1055/s-0034-1370767 ↗
36. Anticancer platelet-mimicking nanovehicles10.1002/adma.201503323 ↗
37. Nanoparticle biointerfacing by platelet membrane cloaking10.1038/nature15373 ↗
38. Recognition, intervention, and monitoring of neutrophils in acute ischemic stroke10.1021/acs.nanolett.9b01282 ↗
39. The natural alkaloid (-)-N-Hydroxyapiosporamide suppresses colorectal tumor progression as an NF-κB pathway inhibitor by targeting the TAK1-TRAF6 complex10.1021/acs.jnatprod.3c00125 ↗
40. Biosynthetic dendritic cell-exocytosed aggregation-induced emission nanoparticles for synergistic photodynamic immunotherapy10.1021/acsnano.2c03597 ↗
41. A size-shrinkable nanoparticle-based combined anti-tumor and anti-inflammatory strategy for enhanced cancer therapy10.1039/C8NR01184B ↗
42. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization10.1002/adma.201606209 ↗
43. Smart one-for-all agent with adaptive functions for improving photoacoustic/fluorescence imaging-guided photodynamic immunotherapy10.1002/smtd.202201582 ↗
44. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
45. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective10.1016/j.ebiom.2024.105301 ↗
46. NIR-II fluorescent nanotheranostics with a switchable irradiation mode for immunogenic sonodynamic therapy10.1002/adma.202411328 ↗
47. PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain10.1038/s41467-021-25416-7 ↗
48. Defeating relapsed and refractory malignancies through a nano-enabled mitochondria-mediated respiratory inhibition and damage pathway10.1016/j.biomaterials.2019.119580 ↗
49. Metabolic reprogramming in modulating T cell reactive oxygen species generation and antioxidant capacity10.3389/fimmu.2018.01075 ↗